The drug is designed to reduce inflammation in the brain and has been used on MS, cancer and migraine headaches.

There is currently no cure for dementia. However, there are treatments and support services that can help someone with the condition. These include drug and non-drug treatments, support, activities, ...

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the finding of new research which also offers a better way to measure the effect ...

IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with ALS in a Phase 2 clinical trial.

A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology firm focused on neurogenetic medicines with a market capitalization of $290 million, announced today it is reassessing its ...

A trial that will test a noninvasive device called MyoRegulator as a treatment for ALS was cleared to start enrolling ...

"The Miami Project and the University of Miami are renowned for their pioneering research in neural interfaces for the treatment of debilitating neurological conditions," Neuralink co-founder and COO ...

Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a study suggests. Similar studies have shown that ...

Financial writer discusses Coya Therapeutics, Inc.'s Treg therapies for neurodegenerative diseases like ALS, FTD, and PD.